Ipca Laboratories Limited
IPCALAB
Rank in Stocks
#3409
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Share Price
$20.02
Last synced: 2026-10-19
Market Cap
$5.08B
Change (1 day)
-1.65%
Change (1 year)
38.46%
Country
IN
Trade Ipca Laboratories Limited (IPCALAB)
Category
Healthcare
Number of shares outstanding for Ipca Laboratories Limited (IPCALAB)
Number of shares outstanding as of June 2026: 253.70M
According to Ipca Laboratories Limited latest financial reports and stock price the company's current number of shares outstanding is 253.70M. At the end of March 2024 the company had 253.70M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Ipca Laboratories Limited (IPCALAB) from 2005 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 253.70M | 0.00% |
| 2025 | 253.70M | 0.00% |
| 2024 | 253.70M | 0.00% |
| 2023 | 253.70M | 0.00% |
| 2022 | 253.70M | 0.17% |
| 2021 | 253.28M | 0.16% |
| 2020 | 252.89M | 0.09% |
| 2019 | 252.65M | 0.09% |
| 2018 | 252.42M | 0.01% |
| 2017 | 252.40M | -0.01% |
| 2016 | 252.41M | 0.01% |
| 2015 | 252.40M | 0.00% |
| 2014 | 252.40M | 0.03% |
| 2013 | 252.32M | 0.08% |
| 2012 | 252.11M | 0.52% |
| 2011 | 250.81M | 0.41% |
| 2010 | 249.79M | -0.51% |
| 2009 | 251.07M | 0.31% |
| 2008 | 250.31M | 0.12% |
| 2007 | 250.00M | 0.00% |
| 2006 | 250.00M | 0.00% |
| 2005 | 250.00M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 845.72% |
IN
|
